FDA grants Orphan Drug Designation to Faron’s bexmarilimab in AML
The ODD will offer clinical development and commercialisation benefits that will strengthen the drug programme
Read More
Tag: Faron Pharmaceuticals
Faron stock falls on traumakine failure
Shares Finnish group Faron Pharmaceuticals were trading down more than 80 percent on the London Stock Exchange after its key drug traumakine failed in acute respiratory distress syndrome (ARDS).
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
